Prolymphocytic leukaemia is a rare and aggressive form of blood cancer that develops when certain white blood cells grow out of control in the bone marrow and bloodstream, affecting mainly adults over the age of 60 with a tendency to progress rapidly and spread throughout the body.
What is Prolymphocytic Leukaemia?
Prolymphocytic leukaemia, often shortened to PLL, is an uncommon type of cancer that begins in the blood-forming tissues of the body. The condition develops when white blood cells called prolymphocytes (a type of immature immune cell) multiply uncontrollably in the bone marrow, the spongy tissue inside bones where blood cells are made. These abnormal cells eventually spill into the bloodstream and spread to other parts of the body, including the spleen, liver, lymph nodes, and sometimes the skin.[1]
PLL is closely related to a more common blood cancer called chronic lymphocytic leukaemia, or CLL. However, PLL behaves quite differently. While CLL typically grows slowly over many years, PLL tends to advance much more rapidly. The cancer cells in PLL grow and spread faster, which makes the disease more aggressive and harder to manage over time. This rapid progression is one of the key features that sets PLL apart from other types of leukaemia.[1]
There are two main types of prolymphocytic leukaemia, classified according to which kind of white blood cell becomes cancerous. The most common form is B-cell prolymphocytic leukaemia, or B-PLL, which accounts for about 80% of all PLL cases. This type affects B lymphocytes, cells that normally help produce antibodies to fight infections. The less common form is T-cell prolymphocytic leukaemia, or T-PLL, which makes up the remaining 20% of cases and involves T lymphocytes, another type of white blood cell that helps coordinate immune responses. Both forms are extremely rare, even when compared to other types of leukaemia.[1]
The World Health Organization has recognized both B-PLL and T-PLL as distinct diseases, separate from chronic lymphocytic leukaemia. However, there is ongoing scientific debate about whether B-PLL is truly a unique disease or whether it represents a transformation of a slower-growing cancer, such as CLL or mantle cell lymphoma, into a more aggressive form. Despite this uncertainty, both types of PLL are treated as separate conditions in clinical practice.[1]
Epidemiology: How Common is Prolymphocytic Leukaemia?
Prolymphocytic leukaemia is exceptionally rare, making it one of the least common forms of blood cancer. T-cell prolymphocytic leukaemia, for instance, represents only about 2% of all mature lymphocytic leukaemias in adults. In practical terms, this means that very few people are diagnosed with the condition each year. In the United Kingdom, approximately 70 people are diagnosed with T-cell PLL annually, giving you an idea of just how uncommon this disease is. Because of its rarity, many people have never heard of PLL before receiving a diagnosis, and it can be difficult to find others who have experienced the same condition.[2][3]
PLL primarily affects older adults, with the median age of diagnosis falling around 65 to 69 years old. While the disease can technically occur in people as young as their 30s, cases in younger individuals are extremely unusual. The vast majority of patients are in their 60s or older when they first develop symptoms. The disease affects men and women in roughly equal numbers, with no strong gender preference observed in most studies. However, some research suggests a slight tendency toward more male patients, particularly in T-cell PLL.[2][3]
One notable exception to the typical age pattern occurs in people with a genetic condition called ataxia telangiectasia, or ATM. This is a rare inherited disorder that causes progressive problems with movement and coordination, along with an increased risk of cancer. Individuals with ataxia telangiectasia have a much higher chance of developing T-cell prolymphocytic leukaemia, and when they do, the cancer often appears at a younger age than would normally be expected. Between 80% and 90% of people with T-cell PLL have mutations in the ATM gene, even if they don’t have the full ataxia telangiectasia syndrome.[2]
B-cell prolymphocytic leukaemia is also very rare, making up less than 1% of all B-cell leukaemias. Like T-PLL, it tends to affect older adults, with an average age of diagnosis around 69 years. Men are slightly more likely to develop B-PLL than women, though the difference is not dramatic. Because both forms of PLL are so uncommon, large-scale population studies are difficult to conduct, and much of what we know about the disease comes from small groups of patients followed over time.[11][15]
Causes of Prolymphocytic Leukaemia
The exact cause of prolymphocytic leukaemia remains largely unknown, though researchers have made significant progress in understanding the genetic changes that drive the disease. PLL develops when errors, or mutations, occur in the DNA of bone marrow cells. These mutations cause the cells to behave abnormally, growing and dividing without the usual controls that keep cell numbers in check. Over time, the abnormal cells accumulate in the bone marrow, blood, and other organs, crowding out healthy cells and disrupting normal bodily functions.[1]
In B-cell prolymphocytic leukaemia, scientists believe that the disease does not typically arise on its own as a brand-new condition. Instead, B-PLL is thought to develop when a slower-growing B-cell cancer, such as chronic lymphocytic leukaemia or mantle cell lymphoma, transforms into a more aggressive form. This transformation involves additional genetic changes that accelerate the growth and spread of cancer cells. However, the precise genetic causes of B-PLL are still not fully understood, and research in this area is ongoing.[1]
T-cell prolymphocytic leukaemia has been studied more extensively in terms of its genetic underpinnings. The most common genetic abnormality in T-PLL involves a change in a gene called TCL-1, which normally helps regulate cell growth and division. When mutations or chromosomal rearrangements affect this gene, it can become an oncogene (a gene that promotes cancer development), triggering the uncontrolled growth of T cells. Researchers have also identified mutations in several other genes, including IL2RG, JAK1, JAK3, STAT5B, EZH2, FBXW10, and CHEK2, all of which play roles in cell cycle regulation and immune function.[2][4]
Chromosomal abnormalities are particularly common in T-cell prolymphocytic leukaemia. About 80% of patients have an inversion of chromosome 14, a rearrangement where part of the chromosome flips around. Another 10% have a translocation, where pieces of two different chromosomes swap places. Additionally, abnormalities of chromosome 8 are seen in approximately 75% of patients, including duplications, translocations, and an extra copy of the chromosome. These genetic changes disrupt the normal regulation of cell growth and contribute to the aggressive nature of the disease.[4]
Importantly, there are no known environmental risk factors for T-cell prolymphocytic leukaemia. Unlike some cancers that can be linked to smoking, radiation exposure, or chemical exposure, T-PLL does not appear to be caused by anything in a person’s environment or lifestyle. The genetic changes that lead to PLL occur spontaneously, and there is no evidence that the disease can be prevented through lifestyle modifications.[2]
Risk Factors for Prolymphocytic Leukaemia
While the exact causes of prolymphocytic leukaemia are not fully understood, several factors have been identified that may increase a person’s likelihood of developing the disease. The most significant risk factor is age. PLL is overwhelmingly a disease of older adults, with most patients diagnosed in their 60s or 70s. The risk of developing PLL increases steadily with advancing age, and cases in people under 60 are uncommon. This age-related pattern suggests that the accumulation of genetic mutations over a lifetime may contribute to the development of the disease.[2]
The most well-established genetic risk factor for T-cell prolymphocytic leukaemia is the presence of ataxia telangiectasia mutation, or ATM. People with the rare inherited disorder ataxia telangiectasia have a significantly increased risk of developing T-PLL, often at a younger age than typical. Even among people who do not have the full syndrome, mutations in the ATM gene on chromosome 11 are found in 80% to 90% of T-PLL patients. This suggests that problems with the ATM gene play a central role in the development of the disease.[2]
A family history of blood or bone marrow cancers may also increase the risk of developing B-cell prolymphocytic leukaemia. People who have close relatives with leukaemia, lymphoma, or other blood disorders appear to have a slightly higher chance of developing B-PLL themselves. However, most people with PLL do not have any family history of cancer, indicating that hereditary factors are not the primary driver of the disease.[11]
In rare cases, T-cell prolymphocytic leukaemia has been associated with certain medical conditions or treatments. There have been isolated reports of T-PLL developing in patients who have undergone kidney transplantation and are taking immunosuppressive medications to prevent organ rejection. There is also a rare association between T-PLL and breast cancer, though the nature of this relationship is not well understood. These associations are extremely uncommon and account for only a tiny fraction of PLL cases.[2]
Being male appears to be a modest risk factor for both types of PLL. While the disease can affect both men and women, some studies have found a slight male predominance, particularly in T-cell PLL. However, the difference is not dramatic, and both sexes are affected in roughly equal numbers overall. Unlike many other cancers, there are no known lifestyle or environmental risk factors for PLL, such as smoking, alcohol consumption, diet, or exposure to chemicals or radiation.[2]
Symptoms of Prolymphocytic Leukaemia
The symptoms of prolymphocytic leukaemia can vary considerably from person to person, and they often depend on which type of PLL a person has. Some individuals have no symptoms at all when they are first diagnosed, with the disease being discovered incidentally during routine blood tests performed for other reasons. However, many people do experience symptoms, and these tend to worsen as the disease progresses.[3]
One of the most common symptoms of PLL is fatigue, a deep and persistent tiredness that doesn’t improve with rest. This happens because the abnormal white blood cells crowd out the production of healthy red blood cells in the bone marrow, leading to anaemia (a condition where you don’t have enough red blood cells to carry oxygen throughout your body). With less oxygen reaching your tissues and organs, you may feel constantly exhausted, weak, and short of breath, even with minimal physical activity. Some people also experience dizziness or lightheadedness, particularly when standing up quickly.[3]
Many patients with PLL develop an enlarged spleen, a condition known as splenomegaly. The spleen is an organ located in the upper left part of your abdomen, and when it enlarges, it can cause a feeling of fullness, discomfort, or pain in that area. Some people describe a sense of bloating or pressure, and the enlarged spleen may make it difficult to eat large meals. The liver can also become enlarged, causing similar symptoms of abdominal discomfort or a feeling of fullness in the upper right side of the abdomen.[1]
Fever, night sweats, and unexplained weight loss are common in both B-cell and T-cell prolymphocytic leukaemia. These are sometimes referred to as “B symptoms” when they occur in blood cancers. Night sweats can be particularly drenching, soaking through clothing and bedding, and they often disrupt sleep. Weight loss occurs without any effort to diet or reduce food intake, and it can be quite rapid in some cases. These symptoms are signs that the body is responding to the presence of cancer cells.[1]
B-cell and T-cell prolymphocytic leukaemia differ in some of their specific symptoms. B-PLL typically involves limited or no swelling of the lymph nodes, the small bean-shaped glands found throughout the body. In contrast, T-PLL often causes noticeable swelling of lymph nodes, particularly in the neck, armpits, and groin. T-PLL also has a greater tendency to affect the skin, causing rashes, lesions, or reddish patches that may look different depending on a person’s skin tone. Skin involvement is rarely seen in B-PLL.[1][3]
Another symptom that can occur in both types of PLL is easy bruising or bleeding. This happens because the abnormal cells in the bone marrow interfere with the production of platelets, the tiny cell fragments that help blood clot. With low platelet counts, a condition called thrombocytopenia, people may notice that they bruise easily from minor bumps, have frequent nosebleeds, or experience bleeding gums when brushing their teeth. Women may have heavier or prolonged menstrual periods.[3]
In T-cell prolymphocytic leukaemia specifically, patients may develop swelling around the eyes or in the legs. This swelling is caused by a buildup of fluid in the tissues and can be uncomfortable or even painful. Some people also experience skin lesions or a reddish rash, which can appear anywhere on the body. Blood tests in T-PLL typically reveal very high white blood cell counts, often exceeding 100,000 cells per microliter, along with low red blood cell and platelet counts.[3][4]
Prevention of Prolymphocytic Leukaemia
Unfortunately, there are no known ways to prevent prolymphocytic leukaemia. Because the disease is caused by spontaneous genetic mutations that occur randomly within cells, and because there are no identified environmental or lifestyle risk factors, it is not possible to reduce your risk through changes in behavior, diet, or lifestyle choices. Unlike some cancers that can be prevented through measures such as avoiding tobacco, limiting alcohol consumption, or protecting your skin from sun exposure, PLL does not have any such preventive strategies.[2]
For people who have the genetic condition ataxia telangiectasia, which increases the risk of developing T-cell prolymphocytic leukaemia, there are currently no specific screening programs or preventive measures available. However, individuals with this condition should be under regular medical supervision for all aspects of their health, and any unusual symptoms should be reported promptly to a healthcare provider. Early detection of blood abnormalities through routine blood tests may allow for earlier intervention, though this has not been proven to change outcomes.[2]
Although prevention is not possible, maintaining overall good health through a balanced diet, regular physical activity, adequate sleep, and stress management can support your immune system and general well-being. These healthy habits may not prevent PLL, but they can help your body function optimally and may improve your ability to tolerate treatment if cancer does develop. It’s also important to attend routine medical check-ups and report any persistent or unusual symptoms to your doctor, as early detection of blood disorders may lead to better outcomes.[2]
Pathophysiology: How Prolymphocytic Leukaemia Affects the Body
To understand how prolymphocytic leukaemia affects the body, it helps to know what happens in healthy bone marrow and blood. Normally, the bone marrow produces blood stem cells that mature into three main types of blood cells: red blood cells that carry oxygen, white blood cells that fight infections, and platelets that help blood clot. This process is carefully regulated to ensure that the right numbers of each cell type are produced and that old or damaged cells are removed.[1]
In prolymphocytic leukaemia, genetic mutations cause certain white blood cells to malfunction. Instead of maturing properly and performing their intended roles in the immune system, these cells become locked in an immature state or develop abnormal characteristics. They begin to multiply rapidly and uncontrollably, ignoring the signals that would normally tell them to stop dividing or to die. As these abnormal prolymphocytes accumulate in the bone marrow, they take up more and more space, leaving less room for the production of healthy blood cells.[1]
As the disease progresses, the abnormal cells spill out of the bone marrow and enter the bloodstream. In many patients, the number of abnormal white blood cells in the blood becomes extremely high, sometimes exceeding 100,000 cells per microliter. This is far above the normal range and can lead to various complications. The leukaemia cells also travel through the bloodstream to other parts of the body, particularly the spleen, liver, lymph nodes, and skin, where they accumulate and cause organ enlargement or dysfunction.[1]
The crowding out of normal blood cell production has serious consequences. With fewer red blood cells being made, patients develop anaemia, which deprives tissues and organs of the oxygen they need to function properly. This leads to fatigue, weakness, shortness of breath, and other symptoms related to poor oxygen delivery. The reduction in platelet production causes thrombocytopenia, increasing the risk of bleeding and bruising. Paradoxically, despite having very high white blood cell counts, patients with PLL often have weakened immune systems because the abnormal white blood cells don’t function properly and can’t fight infections effectively.[1]
In the spleen, the accumulation of leukaemia cells causes the organ to enlarge, sometimes dramatically. An enlarged spleen can cause discomfort and may trap and destroy even more blood cells, worsening anaemia and thrombocytopenia. Similarly, when leukaemia cells infiltrate the liver, it can become enlarged and may not function as efficiently in processing toxins and producing essential proteins. In T-cell prolymphocytic leukaemia, the infiltration of skin by cancer cells causes visible rashes or lesions, and the accumulation of cells in lymph nodes causes them to swell.[1]
The rapid growth and spread of prolymphocytic leukaemia cells is driven by multiple genetic abnormalities. In T-cell PLL, chromosomal rearrangements involving the TCL-1 gene lead to overproduction of a protein that promotes cell survival and proliferation. Mutations in genes that normally regulate cell growth, such as JAK1, JAK3, and STAT5B, remove the brakes on cell division, allowing cells to multiply without restraint. Other mutations affect genes involved in DNA repair or cell death pathways, further contributing to the accumulation of abnormal cells.[2]
The aggressive nature of prolymphocytic leukaemia is reflected in its rapid doubling time. T-cell PLL, in particular, has one of the fastest doubling times of any leukaemia, meaning the number of cancer cells can increase very quickly. This rapid proliferation explains why the disease often presents with very high white blood cell counts at diagnosis and why symptoms can worsen rapidly if left untreated. The fast growth also makes PLL more challenging to control with treatment compared to slower-growing blood cancers.[2]
